Enhanced wild-type p53 expression by small activating RNA dsP53-285 induces cell cycle arrest and apoptosis in pheochromocytoma cell line PC12

Lin,Dengqiang; Meng,Li; Xu,Feifei; Lian,Jianpo; Xu,Yunze; Xie,Xin; Wang,Xiaojing; He,Hongchao; Wang,Chenghe; Zhu,Yu

doi:10.3892/or.2017.5993

Enhanced wild-type p53 expression by small activating RNA dsP53-285 induces cell cycle arrest and apoptosis in pheochromocytoma cell line PC12

Authors:
- Dengqiang Lin
- Li Meng
- Feifei Xu
- Jianpo Lian
- Yunze Xu
- Xin Xie
- Xiaojing Wang
- Hongchao He
- Chenghe Wang
- Yu Zhu
View Affiliations

Affiliations: Department of Urology, Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai 200025, P.R. China, Department of Urology, Renji Hospital Affiliated to the Medical School of Shanghai Jiaotong University, Shanghai 200000, P.R. China
Published online on: September 25, 2017 https://doi.org/10.3892/or.2017.5993
Pages: 3160-3166

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant pheochromocytoma (PHEO) is diagnosed only when metastasis has occurred, making it less likely for patients to obtain the benefits of traditional chemotherapy. Anti-oncogene TP53 mutation has been detected in PHEO and is possibly related to disease progression. However, whether the upregulation of wild-type TP53 has antitumoral effects on PHEO remains completely unknown. In the present study, we used RNA activation (RNAa) technique to upregulate the expression of wild-type TP53 by transfecting synthetic dsP53‑285 into PHEO cell line PC12. We found that the upregulation of wild-type p53 blocked the transition of PC12 cells from the G0/G1 to the S phase, with induction of apoptosis. Additionally, the above-mentioned findings were attested in vivo. Most importantly, dsP53-285-induced antitumoral effects were reversible following co-transfection with siRNA that targeted p53 mRNA. Collectively, our results revealed that the upregulation of p53 and possibly other anti-oncogenes may provide a potential effective therapeutic strategy for PHEO.

View Figures

View References

1	Walther MM, Herring J, Enquist E, Keiser HR and Linehan WM: von Recklinghausen's disease and pheochromocytomas. J Urol. 162:1582–1586. 1999. View Article : Google Scholar : PubMed/NCBI
2	Edström Elder E, Skog AL Hjelm, Höög A and Hamberger B: The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol. 29:278–283. 2003. View Article : Google Scholar : PubMed/NCBI
3	Schürmeyer T, Dralle H, Schuppert F and von zur Mühlen A: Preoperative diagnosis of suspected pheochromocytoma - retrospective assessment of diagnostic criteria. Acta Med Austriaca. 15:106–108. 1988.(In German). PubMed/NCBI
4	Roman-Gonzalez A and Jimenez C: Malignant pheochromocytoma-paraganglioma: Pathogenesis, TNM staging, and current clinical trials. Curr Opin Endocrinol Diabetes Obes. 24:174–183. 2017. View Article : Google Scholar : PubMed/NCBI
5	Kopf D, Goretzki PE and Lehnert H: Clinical management of malignant adrenal tumors. J Cancer Res Clin Oncol. 127:143–155. 2001. View Article : Google Scholar : PubMed/NCBI
6	Muller PA and Vousden KH: Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell. 25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
7	Vousden KH and Lu X: Live or let die: The cell's response to p53. Nat Rev Cancer. 2:594–604. 2002. View Article : Google Scholar : PubMed/NCBI
8	Oren M: Decision making by p53: Life, death and cancer. Cell Death Differ. 10:431–442. 2003. View Article : Google Scholar : PubMed/NCBI
9	Vousden KH and Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar : PubMed/NCBI
10	Lin SR, Lee YJ and Tsai JH: Mutations of the p53 gene in human functional adrenal neoplasms. J Clin Endocrinol Metab. 78:483–491. 1994. View Article : Google Scholar : PubMed/NCBI
11	Yoshimoto T, Naruse M, Zeng Z, Nishikawa T, Kasajima T, Toma H, Yamamori S, Matsumoto H, Tanabe A, Naruse K, et al: The relatively high frequency of p53 gene mutations in multiple and malignant phaeochromocytomas. J Endocrinol. 159:247–255. 1998. View Article : Google Scholar : PubMed/NCBI
12	Huang V, Qin Y, Wang J, Wang X, Place RF, Lin G, Lue TF and Li LC: RNAa is conserved in mammalian cells. PLoS One. 5:e88482010. View Article : Google Scholar : PubMed/NCBI
13	Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science. 253:49–53. 1991. View Article : Google Scholar : PubMed/NCBI
14	Milner J, Medcalf EA and Cook AC: Tumor suppressor p53: Analysis of wild-type and mutant p53 complexes. Mol Cell Biol. 11:12–19. 1991. View Article : Google Scholar : PubMed/NCBI
15	Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R and Ishioka C: Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA. 100:pp. 8424–8429. 2003; View Article : Google Scholar : PubMed/NCBI
16	Schlomm T, Iwers L, Kirstein P, Jessen B, Köllermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, et al: Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol. 21:1371–1378. 2008. View Article : Google Scholar : PubMed/NCBI
17	Ge Q, Wang C, Ruan Y, Chen Z, Liu J and Ye Z: Overexpression of p53 activated by small activating RNA suppresses the growth of human prostate cancer cells. Onco Targets Ther. 9:231–241. 2016.PubMed/NCBI
18	Wang C, Ge Q, Zhang Q, Chen Z, Hu J, Li F and Ye Z: Targeted p53 activation by saRNA suppresses human bladder cancer cells growth and metastasis. J Exp Clin Cancer Res. 35:532016. View Article : Google Scholar : PubMed/NCBI
19	Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T and Hannon GJ: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 377:552–557. 1995. View Article : Google Scholar : PubMed/NCBI
20	Waldman T, Kinzler KW and Vogelstein B: p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55:5187–5190. 1995.PubMed/NCBI
21	Del Sal G, Murphy M, Ruaro E, Lazarevic D, Levine AJ and Schneider C: Cyclin D1 and p21/waf1 are both involved in p53 growth suppression. Oncogene. 12:177–185. 1996.PubMed/NCBI
22	Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinases. Nature. 366:701–704. 1993. View Article : Google Scholar : PubMed/NCBI
23	Waga S, Hannon GJ, Beach D and Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 369:574–578. 1994. View Article : Google Scholar : PubMed/NCBI
24	Plati J, Bucur O and Khosravi-Far R: Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities. J Cell Biochem. 104:1124–1149. 2008. View Article : Google Scholar : PubMed/NCBI
25	Fulda S: Tumor resistance to apoptosis. Int J Cancer. 124:511–515. 2009. View Article : Google Scholar : PubMed/NCBI
26	Groeger AM, Esposito V, De Luca A, Cassandro R, Tonini G, Ambrogi V, Baldi F, Goldfarb R, Mineo TC, Baldi A, et al: Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers. Histopathology. 44:54–63. 2004. View Article : Google Scholar : PubMed/NCBI
27	Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, Enokida H and Dahiya R: Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci USA. 103:pp. 17337–17342. 2006; View Article : Google Scholar : PubMed/NCBI
28	Place RF, Noonan EJ, Földes-Papp Z and Li LC: Defining features and exploring chemical modifications to manipulate RNAa activity. Curr Pharm Biotechnol. 11:518–526. 2010. View Article : Google Scholar : PubMed/NCBI